Biomarker Research for Personalized Medicine

This study is currently recruiting participants.
Verified May 2013 by Inje University
Sponsor:
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University
ClinicalTrials.gov Identifier:
NCT01488591
First received: December 6, 2011
Last updated: May 30, 2013
Last verified: May 2013
  Purpose

The aim of this study :

  1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
  2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping

Condition
Hematologic Neoplasms

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Biomarker Research for Personalized Medicine in Blood Cancer Patient

Resource links provided by NLM:


Further study details as provided by Inje University:

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 1000
Study Start Date: April 2009
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

healthy volunteers

Criteria

Inclusion Criteria:

  • Korean
  • Clinical diagnosis of Hematologic neoplasms
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01488591

Contacts
Contact: Jae Gook Shin, M.D.,Ph.D. 82-51-890-6709 phshinjg@inje.ac.kr

Locations
Korea, Republic of
Inje University Recruiting
Busan, Korea, Republic of, 614-735
Contact: Jae Gook Shin, M.D., Ph.D.    82-51-890-6709    phshinjg@inje.ac.kr   
Sponsors and Collaborators
Inje University
  More Information

No publications provided

Responsible Party: Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University
ClinicalTrials.gov Identifier: NCT01488591     History of Changes
Other Study ID Numbers: 09-029
Study First Received: December 6, 2011
Last Updated: May 30, 2013
Health Authority: Korea: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases

ClinicalTrials.gov processed this record on April 23, 2014